Skip to main content
Signal8

AC Immune SA (ACIU)

AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

AC Immune S.A. logo

AC Immune S.A.

NASDAQ:ACIUHealthcare
-4.55%$2.31
AH Close$2.31+0.00%vs close
Mkt Cap$229.68M
Float74.67M
O/S99.43M
Inst Own24.6%
SI4.4%
Dilution
AC Immune S.A. logoNASDAQ:ACIU$2.31-4.55%
Delisting Issues Timeline
Financials Summary
Revenue$4.32M
Net Income-$85.27M
Total Assets$186.92M
Free Cash Flow-$81.11M
Debt & Equity
Debt 9%
Equity 91%
Total Debt$5.5M
Total Equity$54.39M
Shares Outstanding
Short Interest
Split History

No splits on record

Nothing in ACIU's public trading history: no forward or reverse split has affected the share count.

Balance Sheet Details
Assets$186.92M
Liabilities$132.53M
Accounts Receivable$1.62M
Accounts Payable$2.5M
Inventory$0
PP&E (Net)$7.91M
Goodwill$0
Intangible Assets$61.09M
Income Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Revenue$4.32M$33.06M$17.92M$4.76M$0$18.68M$133.7M$8.71M$24.52M$28.1M$47.32M$36.64M$10.45M
YoY Growth-86.9%84.5%276.1%---86.0%1435.4%-64.5%-12.7%-40.6%29.1%250.5%-
Cost of Revenue$0$75.74M$66.1M$0$0$72M$61.04M$53.59M$39.54M$31.2M$20.64M$19.51M$20.8M
Gross Profit$4.32M-$42.68M-$48.18M$4.76M$0-$53.33M$72.65M-$44.89M-$15.02M-$3.1M$26.68M$17.13M-$10.34M
Gross Margin100.0%-129.1%-268.9%100.0%--285.5%54.3%-515.5%-61.3%-11.0%56.4%46.8%-98.9%
Research and Development$68.31M$75.74M$66.1M$73.03M$75.39M$72M$61.04M$53.59M$39.54M$31.2M$20.64M$19.51M$20.8M
Selling, General, and Administrative$14.1M$13.84M$12.8M$11.6M$13.17M$22.46M$19.44M$9.16M$7.59M$5.72M$2.47M$2.42M$3.58M
Other$5.26M-$68.86M-$62.17M$5.89M$7.08M-$73.64M-$61.73M$5.93M$4.67M$3.83M$1.67M$1.74M$0
Total Operating Expenses$87.68M$20.72M$16.73M$90.52M$95.64M$20.82M$18.75M$68.68M$51.8M$40.76M$24.77M$23.67M$3.34M
Operating Income (EBIT)-$83.35M-$63.4M-$64.91M-$85.76M-$95.64M-$74.15M$53.91M-$59.98M-$27.28M-$12.66M$22.54M$12.97M-$13.92M
Operating Margin-1927.3%-191.8%-362.3%-1800.4%--397.0%40.3%-688.8%-111.3%-45.0%47.6%35.4%-133.1%
Interest Expense$231K$161K$213K$430K$703K$223K$2.33M$404K$178K$310K$31K$5K$0
Interest Income$2.26M$3.87M$1.26M$84K$7.85M$94K$367K$154K$399K$52K$67K$27K$70K
Other Income (Expense)-$1.92M$1.77M-$725K$130K$7.28M-$800K$1.1M-$1.7M-$4.69M$4.07M$1.99M$33K$309K
Income Before Tax (EBT)-$85.27M-$61.63M-$65.63M-$85.63M-$88.35M-$74.95M$55M-$61.67M-$31.97M-$8.59M$24.54M$13M-$13.61M
Income Tax Expense$0$4K$12K$16K$4K$0$0$0$178K$0$0$38K$0
Net Income-$85.27M-$61.63M-$65.65M-$85.64M-$88.36M-$74.95M$55M-$61.67M-$31.97M-$8.59M$24.54M$13M-$13.61M
Net Income Margin-1971.6%-186.4%-366.4%-1798.0%--401.3%41.1%-708.2%-130.4%-30.6%51.9%35.5%-130.2%
Supplementary Data
EPS-0.70-0.51-0.64-0.85-0.97-0.860.64-0.82-0.46-0.140.370.19-0.28
Diluted EPS-0.70-0.51-0.64-0.85-0.97-0.860.64-0.82-0.46-0.140.370.19-0.28
Weighted Average OS100.75M99.69M84.69M83.55M74.95M71.90M70.60M61.84M57.08M50.10M55.40M55.40M40.59M
EBITDA-$82.01M-$58.85M-$62.74M-$82.34M-$84.74M-$71.77M$55.96M-$60.11M-$27.28M-$8.24M$22.89M$13.33M-$13.56M
EBITDA Margin-1896.2%-178.0%-350.2%-1728.7%--384.2%41.9%-690.2%-111.3%-29.3%48.4%36.4%-129.7%
Balance Sheet
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Assets
Current Assets
Cash and Cash Equivalents$32.47M$43.91M$95.01M$38.23M$99.52M$194.75M$234.32M$189.39M$150.55M$184.24M$92.62M$4M$13.62M
Short-Term Investments$78.3M$156.4M$29.72M$110.15M$140.41M$78.68M$114.99M$36.31M$0$0$0$0$0
Cash and Short-Term Investments$110.65M$200.31M$124.73M$148.38M$239.93M$273.43M$349.31M$225.7M$150.55M$184.24M$92.62M$4M$13.62M
Accounts Receivable$1.62M$1.33M$18.21M$494K$1.18M$1.93M$1.69M$4.97M$4.5M$1.7M$382K$31.46M$0
Inventory$0$0$0$0$0$0$0$0-$1.64M$471K$2.98M$387K$0
Other Current Assets$0$1.34M$753K$474K$518K$398K$0$0$0$0$2.95M$0$231K
Total Current Assets$117.21M$208.19M$151.49M$155.05M$245.27M$280.54M$354.38M$233.53M$156.79M$187.49M$96.04M$35.91M$14.47M
Long-Term Assets
Property, Plant & Equipment Net$7.91M$9.79M$8.33M$8.55M$9.72M$8.04M$7.47M$4.02M$2.85M$1.36M$605K$658K$863K
Goodwill$0$0$0$0$0$0$0$0$0$0$0$0$0
Intangible Assets$61.09M$61.03M$61.03M$61.03M$61.03M$0$0$0$0$0$0$0$0
Long-Term Investments$708K$0$437K$0$0$0$368K$368K$153K$104K$103K$0$0
Deferred Tax Assets$0$0$0$0$0$0$0$0$0$0$0$0$0
Other Long-Term Assets$1K$502K$0$437K$439K$404K$0$0$0$0$0$103K$99K
Total Long-Term Assets$69.71M$71.32M$69.79M$70.02M$71.18M$8.44M$7.84M$4.39M$3M$1.46M$708K$761K$962K
Other Assets$0$0$0$0$0$0$0$0$0$0$0$0$0
Total Assets$186.92M$279.5M$221.28M$225.06M$316.46M$288.98M$362.22M$237.92M$159.79M$188.95M$96.75M$36.67M$15.43M
Liabilities
Current Liabilities
Accounts Payable$2.5M$3.22M$2.03M$1.12M$2.42M$2.64M$172K$2.4M$1.32M$4.88M$2.08M$1.92M$1.5M
Short-Term Debt$0$0$0$0$0$0$789K$402K$0$0$0$0$0
Current Income Tax Payable$0$0$0$0$0$0$0$0$0$0$0$0$0
Current Unearned Revenue$101.32M$0$167K$0$0$0$5.42M$425K$430K$631K$54K$248K$0
Other Current Liabilities$0$102.95M$0$711K$868K$370K$0$0$0$0$0$0$4.75M
Total Current Liabilities$114.75M$122.06M$16.43M$13.9M$24.24M$16.97M$21.19M$15.83M$11.81M$12.01M$7.38M$5.35M$9.55M
Long-Term Liabilities
Long-Term Debt$0$0$0$0$0$0$0$225K$598K$0$0$0$0
Long-Term Unearned Revenue$2.83M$0$0$0$0$0$0$0$0$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0$0$0$0$0$0$0$0$0
Other Long-Term Liabilities$10.48M$16.22M$6.98M$3.89M$8.59M$9.03M$9.06M$6.86M$5.48M$4.6M$3.37M$2.92M$0
Total Long-Term Liabilities$17.78M$21.55M$10.4M$6.62M$11.42M$11.19M$11.25M$7.08M$6.56M$4.6M$3.37M$2.92M$0
Other Liabilities$0$0$0$0$0$0$0$0$0$0$0$0$0
Total Liabilities$132.53M$143.61M$26.84M$20.51M$35.66M$28.16M$32.45M$22.92M$18.37M$16.61M$10.76M$8.27M$9.55M
Stockholders' Equity
Preferred Stock$0$0$0$0$0$0$0$0$0$0$0$0$0
Common Stock$2.73M$2.69M$2.53M$2.18M$2.17M$1.86M$1.74M$1.64M$1.39M$1.37M$1.12M$1.03M$983K
Retained Earnings-$532.01M-$445.73M-$382.73M-$319.57M-$243.23M-$160.81M-$91.41M-$147.52M-$87.89M-$56.79M-$48.88M-$73.18M-$84.84M
Comprehensive Income & Other$8K-$6K-$62K$12K$0$0$0-$4.29M$217.09M-$2.61M-$2.27M-$1.92M$0
Other Stockholders' Equity$583.67M$578.93M$574.65M$521.95M$521.85M$419.76M$419.45M$360.89M$227.92M$227.76M$133.75M$100.55M$88.62M
Total Equity$54.39M$135.89M$194.45M$204.55M$280.79M$260.82M$329.77M$215M$141.43M$172.34M$85.99M$28.41M$4.76M
Minority Interest$0$0$0$0$0$0$0$0$0$0$0$0$0
Total Liabilities and Equity$186.92M$279.5M$221.28M$225.06M$316.46M$288.98M$362.22M$237.92M$159.79M$188.95M$96.75M$36.67M$14.31M
Supplementary Data
Total Debt$5.5M$6.57M$4.23M$3.39M$3.52M$2.69M$3.52M$627K$478K$0$0$0$0
Net Debt-$26.97M-$37.34M-$90.78M-$34.84M-$95.99M-$192.06M-$230.8M-$188.76M-$150.07M-$184.24M-$92.62M-$4M-$13.62M
Cash Flow Statement
PeriodFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Operating Activities
Net Income-$81.44M-$61.63M-$65.65M-$85.64M-$88.36M-$74.95M$55M-$61.67M-$31.97M-$8.59M$24.54M$13M-$13.61M
Depreciation & Amortization$3.03M$2.62M$2.68M$2.86M$2.91M$2.38M$2.05M$1.16M$702K$336K$347K$361K$355K
Deferred Income Tax$0$0$0$0$157K$0$0$159K$214K-$100K$59K$21K$0
Stock-Based Compensation$0$6.62M$5.28M$4.03M$4.99M$4.95M$3.43M$3.05M$1.91M$1.59M$654K$254K$310K
Changes in Working Capital:
  Accounts Receivable$1.06M$16.4M-$17.91M$730K-$120K-$644K$3.03M$845K-$485K-$300K$31.07M-$31.16M$67K
  Inventory$0$0$0$0$0$0$0$0$0$0$0$0$0
  Accounts Payable-$684K$0$0$0$0$0$0$0-$3.45M$3.14M-$171K$413K$0
  Other Working Capital-$8.21M$113.74M-$436K-$10.94M$8.4M-$4.89M$3.81M$2.19M$1.04M$855K$29.93M-$35.35M-$199K
Total Working Capital Change-$7.83M$130.14M-$18.35M-$10.21M$8.28M-$5.54M$6.84M$2.19M-$2.41M$3.99M$29.76M-$34.94M-$132K
Other Non-Cash Items$6.17M$1.95M$2.91M-$87K-$7.5M$1.12M-$484K$1.76M$4.81M-$4.07M-$1.99M-$33K-$10.9M
Net Cash from Operating-$80.07M$79.7M-$73.12M-$89.05M-$79.51M-$72.04M$66.84M-$53.35M-$26.74M-$6.83M$53.36M-$21.33M-$23.97M
Investing Activities
Capital Expenditures-$1.04M-$697K-$970K-$1.5M-$3.19M-$2.06M-$2.28M-$2.25M-$2.18M-$1.09M-$295K-$155K-$301K
Acquisitions$17K$0$0$0$0$0$0$0$0$0$0$0$0
Purchases of Investments$0$0$0$0$0$0-$78.68M-$36.31M$0$0$0$0$0
Sales of Investments$74.67M$0$0$0$0$0$0$0$0$0$0$0$0
Other Investing Activities-$197K-$126.75M$80.43M$30.26M-$61.77M$36.36M$0-$215K-$48K$0$0-$4K$0
Net Cash from Investing$73.46M-$127.45M$79.46M$28.76M-$64.96M$34.29M-$80.96M-$38.78M-$2.23M-$1.09M-$295K-$159K-$301K
Financing Activities
Debt Repaid$1.24M$827K$663K$689K-$27.78M$523K-$60.59M-$240K-$242K--$67K--
Common Stock Issuance$7K$134K$53.01M$8K$21.55M$121K$0$135M$0$84.35M$0$0$0
Common Stock Repurchases$0$0$0-$10K$0-$121K$0$0$0$0$0$0$0
Dividends Paid$0$0$0$0$0$0$0$0$0$0$0$0$0
Other Financing Activities$56K-$663K$0-$939K-$7K$173K-$534K-$2.84M$86K-$4.97M-$2.15M-$241K$12.11M
Net Cash from Financing-$1.18M-$1.36M$52.35M-$1.63M$49.32M-$972K$60.06M$132.39M$328K$95.37M$33.62M$11.86M$12.11M
Forex Effect$1.83M-$2M-$1.91M$631K-$85K-$851K-$1M-$1.43M-$5.05M$4.17M$1.93M$11K$238K
Net Change in Cash-$5.96M-$51.1M$56.78M-$61.28M-$95.23M-$39.57M$44.94M$38.84M-$33.69M$91.61M$88.62M-$9.62M-$11.92M
Supplementary Data
Operating Cash Flow-$80.07M$79.7M-$73.12M-$89.05M-$79.51M-$72.04M$66.84M-$53.35M-$26.74M-$6.83M$53.36M-$21.33M-$23.97M
Capital Expenditure-$1.04M-$697K-$970K-$1.5M-$3.19M-$2.06M-$2.28M-$2.25M-$2.18M-$1.09M-$295K-$155K-$301K
Free Cash Flow-$81.11M$79M-$74.09M-$90.55M-$82.7M-$74.11M$64.56M-$55.6M-$28.92M-$7.92M$53.07M-$21.49M-$24.27M
Cash at Beginning$38.43M$95.01M$38.23M$99.52M$194.75M$234.32M$189.39M$150.55M$184.24M$92.62M$4M$13.62M$25.54M
Cash at End$32.47M$43.91M$95.01M$38.23M$99.52M$194.75M$234.32M$189.39M$150.55M$184.24M$92.62M$4M$13.62M